1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Background Idarucizumab, a monoclonal antibody fragment, was developed to reverse the
anticoagulant effect of dabigatran. Methods We performed a multicenter, prospective, open …

Background Antiviral drugs are administered in patients with severe COVID‐19 respiratory
syndrome, including those treated with direct oral anticoagulants (DOACs). Concomitant …

Importance The comparative effectiveness of rivaroxaban and apixaban, the most frequently
prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial …

Background Specific reversal agents for non–vitamin K antagonist oral anticoagulants are
lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral
anticoagulants Summary One of the key benefits of the direct oral anticoagulants (DOACs) is …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …